Blue Lake Biotechnology is focused on developing intranasal vaccines that utilize a proprietary parainfluenza virus 5 (PIV5)-based vector. This innovative platform is designed to stimulate a comprehensive immune response, engaging the humoral, cellular, and mucosal aspects of the immune system. The company is advancing a pipeline that includes clinical-stage vaccines for Respiratory Syncytial Virus (RSV) and COVID-19, both of which have shown promising safety and efficacy profiles in early clinical trials. The intranasal delivery method not only simplifies administration but also enhances the potential for mucosal immunity, which is crucial for preventing disease transmission.

The RSV vaccine, BLB201, is particularly noteworthy as it encodes the natural full-length F-protein from RSV, which has been shown to be a superior antigen compared to traditional protein-based vaccines. Meanwhile, the COVID-19 vaccine candidate, CVXGA, aims to address vaccine hesitancy by providing a needle-free option that has demonstrated robust immune responses and a significant reduction in symptomatic infections. Blue Lake's approach to vaccine development seeks to overcome the limitations of existing technologies, offering a promising alternative that is easier to manufacture, transport, and administer, while maintaining a strong safety profile.

Georgia

Blue Lake Biotechnology is an intranasal vaccine company enlisting the full force of the immune system to keep people healthy, prevent serious infectious diseases, and save the lives of vulnerable populations. We aspire to transform the healthcare landscape and create a healthier world with better vaccines for all ages that are painless, easy, and effective.

Blue Lake Biotechnology (Subsidiary of Cyanvac)

Company Details